Claims for Patent: 7,276,244

Summary for Patent: 7,276,244

Title:	Methods of treating abnormalities of the first metatarsophalangeal joint of the foot
Abstract:	Disclosed is a method for treating abnormalities of the first metatarsophalangeal joint of the foot of a mammal comprising administering a therapeutically effective amount of neuromuscular toxin to the mammal. Preferred embodiments include administering toxins capable of interfering with the connection between muscle and nerve, e.g. botulinum toxin, to the patient to treat such abnormalities as hallux abductovalgus, hallux varus, hallux limitus, and hallux rigidus.
Inventor(s):	Radovic; Philip (San Clemente, CA)
Assignee:	Radovic; Philip (San Clemente, CA)
Application Number:	11/056,382
Patent Claims:	1. A method for treating abnormalities of the first metatarsophalangeal joint of the foot of a mammal, wherein the joint abnormality is selected from the group consisting of hallux abductovalgus, hallux varus, hallux limitus, or hallux rigidus, comprising administering an amount of a botulinum toxin to the adductor hallucis muscle, abductor hallucis muscle, or flexor hallucis brevis muscle, sufficient to alleviate a symptom of the joint abnormality. 2. The method of claim 1 wherein the joint abnormality is hallux abductovalgus. 3. The method of claim 2 wherein the botulinum toxin is administered to the adductor hallucis muscle. 4. The method of claim 1 wherein the joint abnormality is hallux varus. 5. The method of claim 4 wherein the botulinum toxin is administered to the abductor hallucis muscle. 6. The method of claim 1 wherein the joint abnormality is hallux limitus. 7. The method of claim 6 wherein the botulinum toxin is administered to the flexor hallucis brevis muscle. 8. The method of claim 1 wherein the joint abnormality is hallux rigidus. 9. The method of claim 8 wherein the botulinum toxin is administered to the flexor hallucis brevis muscle. 10. The method of claim 1 wherein the botulinum toxin is administered by intramuscular injection. 11. The method of claim 10 wherein electrical stimulation is used to determine the optimal site or sites for injection. 12. The method of claim 1 wherein the botulinum toxin is botulinum toxin type A. 13. The method of claim 12 wherein the botulinum toxin type A is administered in amount of between about 50 units and about 300 units. 14. The method of claim 1 wherein the botulinum toxin is botulinum toxin type B. 15. The method of claim 1 wherein the botulinum toxin is a mixture of toxins. 16. The method of claim 1 wherein a symptom of the joint abnormality is alleviated for at least 3 months. 17. The method of claim 1 additionally comprising readministering the botulinum toxin. 18. The method of claim 1 additionally comprising immobilizing the foot to maintain position after the toxin has been administered. 19. The method of claim 1 additionally comprising stimulating a muscle opposed to the muscle to which the toxin is administered. 20. The method of claim 1 wherein administration of the botulinum toxin is carried out during surgery on the foot. 21. The method of claim 1 wherein the mammal is a human. 22. The method of claim 1, wherein the botulinum toxin is selected from the group consisting of types A, B, C1, D, E, F and G.

Details for Patent 7,276,244

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	12/08/2000		2024-02-12